<DOC>
	<DOC>NCT00959647</DOC>
	<brief_summary>This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.</brief_summary>
	<brief_title>A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>This study only enrolled participants who took part in previous studies of vismodegib conducted by Genentech. Completed vismodegib treatment within 24 weeks in a Genentechsponsored parent study or continued to receive vismodegib at the time the Genentechsponsored parent study closed. Expectation by the investigator that the participant may continue to benefit from additional vismodegib treatment. Intervening antitumor therapy not specified in the parent study (ie, nonprotocolspecified chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hedgehog pathway inhibitor</keyword>
</DOC>